KBC Group NV Has $334.83 Million Holdings in Eli Lilly and Company (NYSE:LLY)

KBC Group NV reduced its position in shares of Eli Lilly and Company (NYSE:LLYFree Report) by 10.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 574,395 shares of the company’s stock after selling 67,939 shares during the quarter. Eli Lilly and Company makes up about 1.2% of KBC Group NV’s holdings, making the stock its 10th biggest holding. KBC Group NV owned about 0.06% of Eli Lilly and Company worth $334,826,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Stonebridge Financial Planning Group LLC purchased a new position in Eli Lilly and Company during the 3rd quarter valued at $236,000. Pekin Hardy Strauss Inc. grew its position in shares of Eli Lilly and Company by 18.6% in the 3rd quarter. Pekin Hardy Strauss Inc. now owns 1,277 shares of the company’s stock worth $686,000 after buying an additional 200 shares during the period. Bryn Mawr Capital Management LLC grew its position in shares of Eli Lilly and Company by 147.3% in the 3rd quarter. Bryn Mawr Capital Management LLC now owns 3,326 shares of the company’s stock worth $1,787,000 after buying an additional 1,981 shares during the period. Moody Aldrich Partners LLC purchased a new stake in shares of Eli Lilly and Company in the 3rd quarter worth about $1,030,000. Finally, Avantax Advisory Services Inc. grew its position in shares of Eli Lilly and Company by 2.7% in the 3rd quarter. Avantax Advisory Services Inc. now owns 36,493 shares of the company’s stock worth $19,601,000 after buying an additional 958 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 2,052 shares of the stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the completion of the sale, the insider now directly owns 98,554,195 shares of the company’s stock, valued at approximately $79,730,343,755. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Stock Performance

NYSE LLY traded up $13.98 on Monday, reaching $834.32. 1,325,933 shares of the stock were exchanged, compared to its average volume of 2,970,937. Eli Lilly and Company has a one year low of $432.34 and a one year high of $838.28. The firm has a market capitalization of $792.95 billion, a PE ratio of 122.69, a PEG ratio of 1.79 and a beta of 0.36. The company’s 50-day simple moving average is $769.79 and its two-hundred day simple moving average is $700.96. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company (NYSE:LLYGet Free Report) last released its earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. During the same quarter last year, the business earned $1.62 EPS. The firm’s revenue was up 26.0% compared to the same quarter last year. Analysts expect that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Shareholders of record on Thursday, May 16th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 0.62%. The ex-dividend date is Wednesday, May 15th. Eli Lilly and Company’s payout ratio is 76.58%.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on LLY shares. Bank of America upped their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $885.00 target price (up from $815.00) on shares of Eli Lilly and Company in a research report on Tuesday, April 30th. Barclays upped their target price on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. Finally, Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $769.53.

View Our Latest Report on Eli Lilly and Company

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Recommended Stories

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.